Quality and innovation are two hallmarks of AAM member company Zydus Pharmaceuticals (USA) Inc., a subsidiary of Zydus Cadila, India’s fourth-largest pharmaceutical company. Exceptional service to both customers and patients is also a key driver for their success. With nearly 500 products, Zydus is one of the U.S.’s largest manufacturers of generic medicines.
Joe Renner has been an integral part of Zydus ever since the company entered the U.S. generics market in 2005, and is currently serving as the company’s Chairman. He also serves on the AAM Board of Directors.
AAM helps the generics and biosimilars industry speak with one voice on Capitol Hill and in the states, Renner says.
Membership has proven especially valuable during the uncertainty of the Covid era.
Zydus’s 2017 acquisition of Sentynl Therapeutics Inc., a specialty pharmaceutical company based in Solana Beach, CA, has given Zydus a platform to provide value to patients in the U.S. beyond generics. In addition to its expansion into specialty brands, Zydus is committed to complex generics, including oral suspensions, modified release oral solids, transdermals and injectables. Zydus has several first-to-file and 505(b)(2) products in its portfolio and has received FDA approval on 321 abbreviated new drug applications (ANDA).
By Jewel Smith, AAM Senior Director, Operations
Published on September 2, 2021